search
Back to results

Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

Primary Purpose

Endometrial Cancer, Colon Cancer

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Tissue sample from tumor
Sponsored by
Meir Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Endometrial Cancer focused on measuring To asses the biological actions of insulin analogs in primary tumor cells

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)Female

Inclusion Criteria:

  • Patients with Endometrial and Colon Cancer

Exclusion Criteria:

  • None

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    December 27, 2010
    Last Updated
    August 9, 2012
    Sponsor
    Meir Medical Center
    Collaborators
    Tel Aviv University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01267461
    Brief Title
    Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    August 2012
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Meir Medical Center
    Collaborators
    Tel Aviv University

    4. Oversight

    5. Study Description

    Brief Summary
    Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Endometrial Cancer, Colon Cancer
    Keywords
    To asses the biological actions of insulin analogs in primary tumor cells

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Other
    Intervention Name(s)
    Tissue sample from tumor
    Intervention Description
    Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    90 Years
    Eligibility Criteria
    Inclusion Criteria: Patients with Endometrial and Colon Cancer Exclusion Criteria: None
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ilan Bruchim, MD
    Phone
    972-9-7472561
    Email
    ilan.bruchim@clalit.org.il

    12. IPD Sharing Statement

    Learn more about this trial

    Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

    We'll reach out to this number within 24 hrs